Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection

Frösner, Gert; Schomerus, H.; Wiedmann, K. H.; Zachoval, Reinhart; Bayerl, B.; Bäcker, U; Gathof, G.E.; Sugg, U

doi:10.1007/bf02014141

Cited by 40 publications

(24 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is accepted as the Wrst immunological marker to appear following infection and persists throughout the course of chronic HBV infection [1], although in clinical practice it is not always measured at the earliest stages of infection. Its measurement is used to aid clinical diagnosis of HBV infection, to monitor the eYcacy of antiviral therapy, to screen blood and organ donors for the presence of HBV, as well as to permit surveillance of individuals at risk of either acquiring or transmitting the disease [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Multicentre evaluation of the Elecsys® hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays

Jia

Wei

et al. 2009

Med Microbiol Immunol

View full text Add to dashboard Cite

Screening for hepatitis B surface antigen (HBsAg) demands highly sensitive and specific immunoassays with the ability to detect clinically relevant surface gene mutants-the presence of which is an increasing concern and can compromise test results. The objective of the study was to compare the clinical and technical performance of the fully automated Elecsys HBsAg II assay with other widely used HBsAg immunoassays in China. This was a multicentre study in which eight Chinese laboratories compared the Elecsys HBsAg II assay with the Architect HBsAg assay, AxSYM HBsAg assay, or generic microtitre plate (MTP) enzyme-linked immunosorbent assays (manufactured in China) against preselected samples, including recombinant surface gene mutants, and routine clinical samples. Elecsys HBsAg II was the most sensitive assay for detecting positive results in seroconversion samples: up to 14, 11, and 22 days earlier than the Architect, AxSYM, and MTP HBsAg assays, respectively. It also detected all 211 preselected HBsAg-positive specimens and all 13 recombinant HBsAg mutants; the AxSYM and MTP HBsAg assays failed to detect 3 and 10 mutant samples, respectively. Sensitivity was 100% for Elecsys HBsAg II with routine samples, compared with 99.1, 98.9, and 95.2% for the Architect, AxSYM, and MTP HBsAg assays, respectively. In conclusion, it was demonstrated that the Elecsys HBsAg II assay is suitable for routine HBsAg screening in China.

show abstract

Section: Introductionmentioning

confidence: 99%

Multicentre evaluation of the Elecsys® hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays

Jia

Wei

et al. 2009

Med Microbiol Immunol

View full text Add to dashboard Cite

show abstract

“…To date, prognostic markers which allow to predict who will recover spontaneously and who will control the HBV infection have not been established [12]. The importance of hepatitis B surface antigen (HBsAg) as a marker for the control of HBV infection has been known for a long time [13,14,15]. Most recently, reports showed that quantitative assessment of HBsAg might be helpful in the monitoring of the therapy of chronic hepatitis B with pegylated interferon alpha [16].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B-Associated Acute Liver Failure: Immediate Treatment with Entecavir Inhibits Hepatitis B Virus Replication and Potentially Its Sequelae

Jochum¹,

Gieseler²,

Gawlista³

et al. 2009

Digestion

View full text Add to dashboard Cite

Background: Acute hepatitis B virus (HBV) infection is followed by high viral replication rates leading to hepatocyte death and ultimately, in some cases, to acute liver failure (ALF) necessitating liver transplantation. Thus, the objective of treating HBV-induced ALF is to eliminate or significantly suppress HBV replication. Methods/Results: This prospective study (02/2008–02/2009) included 6 patients (1 female and 5 males, median age 35.5 years). HBV DNA and hepatitis B surface antigen (HBsAg) levels were detected, and hepatocyte death was quantified in patients’ sera by (a) M65 ELISA and (b) M30 ELISA. All patients received entecavir treatment at 1 mg daily within 1–18 days after admission. Upon treatment, pathologic parameters rapidly decreased and returned to normal values or trace amounts (HBV DNA) within 3 months in all of the cases. A seroconversion to anti-HBsAg was achieved in 5 out of 6 patients; one patient with late onset of treatment did not seroconvert. M65 and the difference of M65-M30 as a marker for cell necrosis dropped significantly within 1 week of treatment. Conclusion: This preliminary series of 6 patients reveals that immediate treatment of HBV-induced ALF with entecavir is well tolerated and beneficially affects the course of the disease.

show abstract

“…The significance of quantitative measurement of HBsAg has been defined so previously, but because reliability of former tests were low, its use has been limited (4).…”

Section: Introductionmentioning

confidence: 99%

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Günal¹,

Barut²,

Etikán³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: In this study, we aimed to investigate whether quantitative HBsAg and alanine aminotransferase (ALT) levels correlated with Hepatitis B Virus (HBV) DNA levels in patients with HBeAg negative chronic HBV infection. Materials and Methods: Ninetynine patients were divided into two groups; inactive HBsAg carriers (IC) and active carriers (AC) with HBV DNA >2000 IU/mL. These two groups were compared in terms of ALT and HBsAg levels. Quantitative HBsAg measurements were performed with Elecsys HBsAg II Quant assay (Roche Diagnostic) Results: Mean age of patients was 43.11±14.79 years. HBsAg and ALT values of IC and AC patients were 2.47±1.35 log10 IU/mL, 3.59±0.97log10 IU/mL (p=0.0001), and 25.94±13.06 IU/mL, 55.54±82.38 IU/mL (p=0.015), respectively and the difference was significant. When ROC analysis was performed to determine the most appropriate quantitative HBsAg value to define inactive carrier patients, the area under the ROC curve for HBsAg was 0.738 (95% CI:0.637-0.840). A cut-off of 2147 IU/mL revealed sensitivity of 76% and specificity of 70% for diagnosing the IC. Also, a significant correlation was also found between levels of HBV DNA (log) and HBsAg (log) (r: 0.503, p=0.0001). Conclusion: It has been concluded that quantitative measurements of HBsAg could be used to differentiate between IC and AC patients.

show abstract

Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection

Cited by 40 publications

References 9 publications

Multicentre evaluation of the Elecsys® hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays

Multicentre evaluation of the Elecsys® hepatitis B surface antigen II assay for detection of HBsAg in comparison with other commercially available assays

Hepatitis B-Associated Acute Liver Failure: Immediate Treatment with Entecavir Inhibits Hepatitis B Virus Replication and Potentially Its Sequelae

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Contact Info

Product

Resources

About